Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors

• Status: Completed
• Trial end date: 2020-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this pilot clinical trial are: 1) To evaluate the feasibility and acceptability of a new approach to smoking cessation induction treatment in cancer survivors with low social resources, and 2) To assess the effectiveness of said treatment for key events in the process of smoking cessation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jessica Burris
• Collaborators: Kentucky Lung Cancer Research Foundation; Kentucky Lung Cancer Research Program

Criteria

Inclusion Criteria:

• Cervical or head/neck cancer diagnosis in the past 5 years

• Resident of rural and/or Appalachian Kentucky county at cancer diagnosis

• Current smoker of ≥ 10 cigarettes per day, on average

• Age 18-75 years old

• Able to read, write, and understand English

Exclusion Criteria:

• Unreliable phone access

• Smoking cessation treatment use in past 30 days

• Non-cigarette tobacco use in the past 30 days

• Any FDA contraindication for NRT use, including: allergy to nicotine patches and/or nicotine lozenges; severe kidney or liver disease; unstable angina or serious arrhythmia; epilepsy or seizure disorder; myocardial infarction in the past 3 months

• Cognitive or psychiatric disorder that would interfere with ability to provide informed consent or answer survey questions reliably *

• Any of these Diagnostic and Statistical Manual-5 (DSM-5) cognitive and psychiatric disorders would make someone ineligible: bipolar; delusional; dissociative; intellectual developmental; neurocognitive; psychotic; schizophreniform, schizophrenia, and schizoaffective.

• For women: breastfeeding, pregnancy, or plan to become pregnant within 6 months

• For women of childbearing potential: unwillingness to use an effective method of birth control (e.g., abstinence, oral contraceptive) while in this study